Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded down 3.6% during trading on Tuesday . The company traded as low as $21.60 and last traded at $21.98, with a volume of 80,689 shares traded. The stock had previously closed at $22.80.

A number of equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Citigroup Inc. increased their price objective on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a report on Friday. Canaccord Genuity reissued a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a report on Friday, May 6th. Finally, Jefferies Group reissued a “buy” rating and set a $25.00 price objective (up previously from $22.00) on shares of Atara Biotherapeutics in a report on Tuesday, June 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $27.29.

The firm’s market cap is $639.32 million. The stock’s 50-day moving average price is $22.74 and its 200-day moving average price is $19.44.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.05. Analysts anticipate that Atara Biotherapeutics Inc. will post ($2.78) earnings per share for the current year.

In other news, CEO Isaac E. Ciechanover sold 12,000 shares of Atara Biotherapeutics stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $20.53, for a total transaction of $246,360.00. Following the completion of the sale, the chief executive officer now owns 223,228 shares of the company’s stock, valued at $4,582,870.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Haqq sold 1,346 shares of Atara Biotherapeutics stock in a transaction on Monday, August 15th. The stock was sold at an average price of $22.32, for a total value of $30,042.72. Following the sale, the insider now directly owns 295,294 shares of the company’s stock, valued at approximately $6,590,962.08. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Atara Biotherapeutics stock. Schwab Charles Investment Management Inc. boosted its position in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 3.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,121 shares of the company’s stock after buying an additional 1,608 shares during the period. Schwab Charles Investment Management Inc. owned 0.18% of Atara Biotherapeutics worth $1,377,000 as of its most recent SEC filing.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.